Registered title, quoted from ClinicalTrials.gov
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by National Cancer Center / Cancer Hospital, CAMS; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06861777, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Esophageal squamous cell carcinoma diagnosed by histopathology or cytology;
Inclusion criterion 2
Within 2 weeks prior to the first use of the investigational drug, immunosuppressive or systemic hormone therapy was being used to achieve immunosuppressive effects;
Exclusion criterion 9
Diagnosed with other malignant tumors within 5 years prior to the first use of the investigational drug;
Exclusion criterion 18
ECOG PS 0-1;
Inclusion criterion 6
History of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation or allogeneic bone marrow transplantation;
Exclusion criterion 13
Pregnant or lactating women;
Exclusion criterion 19
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06861777, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Sign a informed consent form and voluntarily join this study;
- Esophageal squamous cell carcinoma diagnosed by histopathology or cytology;
- Diagnosed as thoracic esophageal cancer by CT/MRI/EUS and clinically staged as T1b-3N1-2M0 or T3N0M0 (according to AJCC 8th edition);
- Expected to achieve R0 resection;
- Age ≥ 18 years old, regardless of gender;
- ECOG PS 0-1;
- Have not received any anti-tumor treatment for esophageal cancer in the past;
- Plan to undergo surgical treatment after completion of neoadjuvant therapy;
- No surgical contraindications;
- The main organ functions are normal, including:
- Blood routine examination:
neutrocyte count ≥ 1.5 × 109/L Platelet count ≥ 100 × 109/L Hemoglobin ≥ 90 g/L
- Blood biochemistry test:
Total bilirubin ≤ 1.5 × ULN ALT ≤ 2.5×ULN,AST ≤ 2.5×ULN, Serum creatinine ≤ 1.5 × ULN, or creatinine clearance rate ≥ 50 mL/min (Cocheroft Gault formula, see Appendix 2)
- Coagulation function:
INR ≤ 1.5 × ULN APTT ≤ 1.5 × ULN
- Women who have the ability to conceive or men whose spouses have the ability to conceive should use effective contraceptive measures during the study period;
- The subjects showed good compliance and cooperated with follow-up visits;
Exclusion Criteria:
- Tumors or lymph nodes significantly invade adjacent organs of esophageal lesions;
- Patients with supraclavicular lymph node metastasis;
- Individuals at risk of perforation, fistula, etc;
- There are uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage;
- Poor nutritional status, BMI < 18.5 Kg/m2;
- Have a history of allergies to monoclonal antibodies, any components of Adebrelimab, paclitaxel, cisplatin, or other platinum based drugs in the past;
- Have received or are currently receiving any of the following treatments:
- Any radiotherapy, chemotherapy, or other anti-tumor drugs targeting tumors;
- Within 2 weeks prior to the first use of the investigational drug, immunosuppressive or systemic hormone therapy was being used to achieve immunosuppressive effects;
- Received attenuated live vaccine within 4 weeks prior to the first use of the investigational drug;
- Having undergone major surgery or suffered severe trauma within 4 weeks prior to the first use of the investigational drug;
- Suffering from any active autoimmune disease or history of autoimmune disease;
- History of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation or allogeneic bone marrow transplantation;
- There are clinical symptoms or diseases of the heart that have not been well controlled;
- Severe infection (CTCAE>grade 2) occurred within 4 weeks prior to the first use of the investigational drug;
- Discovery of active pulmonary tuberculosis infection through medical history or CT examination;
- Active hepatitis B and hepatitis C exist;
- Diagnosed with other malignant tumors within 5 years prior to the first use of the investigational drug;
- Pregnant or lactating women;
- According to the researchers' assessment, there are other factors that may lead to the forced termination of the study midway.
Quoted from ClinicalTrials.gov, NCT06861777, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06861777, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.